ALVO

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.11
Percentage change -0.83	%

Peers: ABBV PFE MRK LLY AMGN BIIB VRTX GILD REGN BMY

| Held by: IBB BIB IBBQ STXK RFLR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.66	Insider Own	63.80%	Shs Outstand	301.48M	Perf Week	0.76%
Market Cap	3.98B	Forward P/E	80.40	EPS next Y	0.16	Insider Trans	0.00%	Shs Float	109.14M	Perf Month	13.21%
Income	-441.45M	PEG	-	EPS next Q	0.01	Inst Own	5.31%	Short Float	0.40%	Perf Quarter	5.60%
Sales	367.44M	P/S	10.83	EPS this Y	83.28%	Inst Trans	4.43%	Short Ratio	3.71	Perf Half Y	8.73%
Book/sh	-1.14	P/B	-	EPS next Y	140.42%	ROA	-40.28%	Short Interest	0.44M	Perf Year	7.23%
Cash/sh	0.39	P/C	33.65	EPS next 5Y	-	ROE	-	52W Range	9.15 - 18.00	Perf YTD	-0.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-54.98%	52W High	-26.67%	Beta	-0.18
Dividend TTM	-	Quick Ratio	1.92	Sales past 5Y	3.37%	Gross Margin	56.08%	52W Low	44.26%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	2.69	EPS Y/Y TTM	28.65%	Oper. Margin	-12.91%	RSI (14)	61.15	Volatility	3.26% 2.62%
Employees	1026	Debt/Eq	-	Sales Y/Y TTM	493.59%	Profit Margin	-120.14%	Recom	1.75	Target Price	20.25
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	94.64%	Payout	-	Rel Volume	1.22	Prev Close	13.31
Sales Surprise	21.18%	EPS Surprise	52.38%	Sales Q/Q	478.37%	Earnings	Nov 13 AMC	Avg Volume	117.50K	Price	13.20
SMA20	3.10%	SMA50	6.93%	SMA200	5.98%	Trades		Volume	143,561	Change	-0.83%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $17
Oct-20-23	Upgrade	Citigroup	Sell → Neutral	$5 → $10
Sep-21-23	Initiated	Barclays	Equal Weight	$10
Sep-07-22	Initiated	Morgan Stanley	Equal-Weight	$10
Sep-06-22	Downgrade	Citigroup	Buy → Sell	$12 → $5
Jul-26-22	Initiated	Citigroup	Buy	$12

Dec-23-24 04:00AM	Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 (GlobeNewswire) +5.12%
Nov-15-24 02:07AM	Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-13-24 04:05PM	Alvotech Reports Financial Results for the First Nine Months of 2024 (GlobeNewswire)
Nov-07-24 08:00AM	Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 (GlobeNewswire)
Nov-04-24 07:00AM	European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi (golimumab) (GlobeNewswire)
08:30AM	Loading…
Oct-30-24 08:30AM	Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET (GlobeNewswire)
Oct-25-24 08:00AM	Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19 20, 2024 (GlobeNewswire)
Oct-22-24 07:00AM	Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara (ustekinumab) (GlobeNewswire)
Oct-10-24 05:01AM	European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia and Xgeva (GlobeNewswire)
Sep-25-24 05:01AM	Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio (GlobeNewswire)
Aug-26-24 09:15AM	Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-24 04:15PM	Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 (GlobeNewswire) +7.96% +8.72%
04:30AM	European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea (aflibercept) (GlobeNewswire)
Aug-01-24 04:02PM	Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET (GlobeNewswire)
Jul-22-24 06:35AM	STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe (GlobeNewswire)
04:45AM	Loading…
Jul-11-24 04:45AM	Alvotech Announces Closing of Private Debt Financing (GlobeNewswire)
Jul-02-24 09:00AM	Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva (GlobeNewswire)
Jul-01-24 05:35PM	Alvotech Issues New Shares to Holders of Convertible Bonds (GlobeNewswire)
05:10AM	Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 (GlobeNewswire)
Jun-26-24 04:50AM	Alvotech Receives Conversion Notices for Majority of Convertible Bonds (GlobeNewswire) -5.87%
Jun-25-24 09:40AM	Are Medical Stocks Lagging Alvotech (ALVO) This Year? (Zacks)
Jun-24-24 09:23AM	Here's Why You Should Consider Buying Alvotech (ALVO) Stock (Zacks)
Jun-22-24 09:03AM	Did Teva Pharmaceutical Industries Limited (TEVA)'s Pivot to Growth Strategy Help It Get a Positive Rating from Analysts? (Insider Monkey)
Jun-18-24 04:01AM	Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea LD/HD in Europe (GlobeNewswire)
Jun-11-24 04:00AM	Alvotech and STADA add to Strategic Alliance through Denosumab Partnership (GlobeNewswire)
Jun-07-24 04:00AM	Alvotech Announces Strategic Refinancing Agreement (GlobeNewswire)
May-29-24 08:05AM	Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 (GlobeNewswire)
May-21-24 09:52PM	ALVO Stock Earnings: Alvotech Misses EPS for Q1 2024 (InvestorPlace)
05:15PM	Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update (GlobeNewswire)
10:05AM	Alvotech and Dr. Reddys Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia & Xgeva in the U.S., Europe and UK (Business Wire)
07:55AM	Loading…
07:55AM	Teva and Alvotech launch SIMLANDI in US for arthritis (Pharmaceutical Business Review)
May-20-24 08:25PM	Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S. (Business Wire)
May-15-24 09:30AM	Alvotech S.A. Annual General Meeting to be held June 7, 2024 (GlobeNewswire)
May-13-24 08:00AM	Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) (GlobeNewswire)
May-02-24 07:15AM	Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 (GlobeNewswire)
Apr-30-24 04:00AM	U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab) (Business Wire)
Apr-24-24 04:00AM	Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi (golimumab) (GlobeNewswire)
Apr-19-24 06:10AM	Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira (adalimumab) (GlobeNewswire)
Apr-16-24 05:43PM	Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab) (Business Wire)
Apr-03-24 07:41AM	Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 (GlobeNewswire)
Mar-22-24 04:15PM	Alvotech Announces Increase in Number of Own Shares (GlobeNewswire) -11.24%
Mar-20-24 09:52PM	ALVO Stock Earnings: Alvotech Reported Results for Q4 2023 (InvestorPlace)
04:15PM	Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update (GlobeNewswire)
Mar-05-24 04:01PM	Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET (GlobeNewswire)
Feb-29-24 04:05PM	Alvotech Appoints Interim Chief Quality Officer (GlobeNewswire)
Feb-26-24 09:58AM	TEVA Stock Pops 4% as Teva Receives FDA Approval (InvestorPlace) +7.74%
04:25AM	Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share (GlobeNewswire)
Feb-23-24 08:15PM	Alvotech and Teva Announce U.S. Approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira (Business Wire)
Feb-15-24 06:30AM	Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara (ustekinumab) (GlobeNewswire)
Jan-29-24 04:00AM	Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva (GlobeNewswire)
Jan-22-24 10:03AM	Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates (Zacks)
Jan-19-24 11:30AM	Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 (GlobeNewswire) +15.29%
Jan-10-24 03:30AM	STADA and Alvotech secure approval for Uzpruvo, Europes first ustekinumab biosimilar to Stelara (GlobeNewswire)
Jan-03-24 03:30AM	Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea (aflibercept) (GlobeNewswire)
Dec-29-23 04:05AM	Biodexa Appoints Ann Merchant to the Board of Directors (GlobeNewswire)
Nov-29-23 04:00AM	Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi and Simponi Aria (GlobeNewswire)
Nov-28-23 04:15PM	Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update (GlobeNewswire)
04:15PM	Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update (GlobeNewswire)
Nov-21-23 08:00AM	Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET (GlobeNewswire)
Nov-14-23 07:00AM	Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara (ustekinumab) (GlobeNewswire)
Nov-10-23 09:30AM	STADA and Alvotech receive positive CHMP opinion for Europes first ustekinumab biosimilar to Stelara (GlobeNewswire)
Nov-07-23 08:00AM	Alvotech to Present at the Jefferies 2023 London Healthcare Conference (GlobeNewswire)
Oct-12-23 04:00AM	Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04 (GlobeNewswire)
Oct-05-23 01:21PM	Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland (GlobeNewswire)
Oct-03-23 08:29AM	Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair (omalizumab) (Business Wire)
05:00AM	Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair (omalizumab) (GlobeNewswire)
Sep-25-23 04:00AM	Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara® (GlobeNewswire)
Sep-20-23 04:30AM	Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab) (GlobeNewswire)
Sep-11-23 05:00AM	Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Sep-05-23 09:30AM	Alvotech Announces Changes to the Leadership Team (GlobeNewswire)
Aug-30-23 04:15PM	Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update (GlobeNewswire)
Aug-29-23 05:00AM	Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt (GlobeNewswire)
Aug-22-23 09:15AM	Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET (GlobeNewswire)
Jul-31-23 04:00AM	Alvotech Completes $100 Million Convertible Bond Private Placement (GlobeNewswire)
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE)
Jul-24-23 04:00AM	Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership (GlobeNewswire)
Jul-06-23 07:26AM	Should You Exit Alvotech (ALVO)? (Insider Monkey)
Jun-28-23 07:00PM	Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02 (GlobeNewswire) -6.12%
Jun-12-23 07:00AM	Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara® (Business Wire) -9.51%
May-31-23 05:20AM	Alvotech to Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-24-23 05:00AM	Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe (GlobeNewswire)
May-19-23 05:00AM	Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update (GlobeNewswire)
May-17-23 05:00AM	Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit (GlobeNewswire) -7.35%
May-15-23 05:00AM	Alvotech Issues Annual Equality Report Covering 2022 (GlobeNewswire)
May-10-23 05:00AM	Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept) (GlobeNewswire)
May-05-23 09:00AM	Alvotech S.A. Annual General Meeting to be held June 6, 2023 (GlobeNewswire)
May-04-23 05:00AM	Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® (GlobeNewswire)
May-03-23 09:00AM	Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET (GlobeNewswire)
Apr-19-23 05:30PM	Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer (GlobeNewswire)
Apr-13-23 08:45PM	Alvotech Provides Regulatory Update on AVT02 Biologics License Application (GlobeNewswire) -22.13%
Mar-28-23 05:00AM	Alvotech Provides Update on Corporate Sustainability Framework (GlobeNewswire)
Mar-17-23 09:10AM	Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
Mar-01-23 04:30PM	Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update (GlobeNewswire)
Feb-27-23 07:15PM	Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023 (GlobeNewswire)
Feb-14-23 04:01PM	Updated market making agreement with Landsbankinn for Alvotech shares trading on the Nasdaq Iceland market (GlobeNewswire)
Feb-10-23 04:01PM	Settlement of Alvotech Private Share Placement Completed (GlobeNewswire)
Feb-09-23 02:30AM	EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) (GlobeNewswire)
Feb-06-23 04:00AM	Alvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair® (omalizumab) (GlobeNewswire)
Jan-24-23 04:00AM	Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia (GlobeNewswire)
Jan-23-23 03:25AM	Alvotech Completes $137 Million Private Share Placement (GlobeNewswire)

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Robert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Alvotech

Upgrade your FINVIZ experience